S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Precision BioSciences Stock Forecast, Price & News

-0.53 (-6.08%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
417,000 shs
Average Volume
656,079 shs
Market Capitalization
$497.68 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Precision BioSciences logo

About Precision BioSciences

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.


Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy
November 24, 2021 |  finance.yahoo.com
The Triangle startups on Deloitte's Technology Fast 500
November 17, 2021 |  finance.yahoo.com
Precision BioSciences (NASDAQ:DTIL) Shares Down 6%
November 12, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$24.28 million
Book Value
$1.67 per share


Net Income
$-109.01 million
Pretax Margin




Free Float
Market Cap
$497.68 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.94 out of 5 stars

Medical Sector

703rd out of 1,388 stocks

Biological Products, Except Diagnostic Industry

107th out of 202 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

Is Precision BioSciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Precision BioSciences stock.
View analyst ratings for Precision BioSciences
or view top-rated stocks.

How has Precision BioSciences' stock been impacted by Coronavirus (COVID-19)?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DTIL stock has increased by 26.2% and is now trading at $8.19.
View which stocks have been most impacted by COVID-19

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Precision BioSciences

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) released its earnings results on Wednesday, November, 10th. The company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.59) by $0.40. Precision BioSciences had a negative trailing twelve-month return on equity of 41.63% and a negative net margin of 26.91%. During the same period in the previous year, the business earned ($0.50) EPS.
View Precision BioSciences' earnings history

What price target have analysts set for DTIL?

4 Wall Street analysts have issued 1 year price objectives for Precision BioSciences' stock. Their forecasts range from $14.00 to $27.00. On average, they anticipate Precision BioSciences' stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 168.6% from the stock's current price.
View analysts' price targets for Precision BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Michael Amoroso, President, Chief Executive Officer & Director
  • John Alexander Kelly, Chief Financial & Corporate Affairs Officer
  • Jeff Smith, Chief Technology Officer
  • Derek N. Jantz, Director & Chief Scientific Officer
  • Sinu Bhandaru, Senior Director-Operations & IT

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences CEO Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among Precision BioSciences' employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.02%), ArrowMark Colorado Holdings LLC (3.69%), Geode Capital Management LLC (1.49%), Goldman Sachs Group Inc. (1.11%), CHI Advisors LLC (1.09%) and Principal Financial Group Inc. (0.82%). Company insiders that own Precision BioSciences stock include Christopher Heery, David S Thomson, David S Thomson, Derek Jantz, Matthew R Kane, Matthew R Kane and Vince Craig Hopkin.
View institutional ownership trends for Precision BioSciences

Which major investors are selling Precision BioSciences stock?

DTIL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, ArrowMark Colorado Holdings LLC, Citigroup Inc., State Board of Administration of Florida Retirement System, Integral Health Asset Management LLC, Rafferty Asset Management LLC, and Deutsche Bank AG. Company insiders that have sold Precision BioSciences company stock in the last year include David S Thomson, Derek Jantz, Matthew R Kane, and Vince Craig Hopkin.
View insider buying and selling activity for Precision BioSciences
or view top insider-selling stocks.

Which major investors are buying Precision BioSciences stock?

DTIL stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., BlackRock Inc., Marshall Wace LLP, Opaleye Management Inc., Healthcare of Ontario Pension Plan Trust Fund, Captrust Financial Advisors, Geode Capital Management LLC, and Cinctive Capital Management LP.
View insider buying and selling activity for Precision BioSciences
or or view top insider-buying stocks.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $8.19.

How much money does Precision BioSciences make?

Precision BioSciences has a market capitalization of $497.68 million and generates $24.28 million in revenue each year. The company earns $-109.01 million in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does Precision BioSciences have?

Precision BioSciences employs 231 workers across the globe.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is www.precisionbiosciences.com.

Where are Precision BioSciences' headquarters?

Precision BioSciences is headquartered at 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at (919) 314-5512 or via email at [email protected].

This page was last updated on 12/6/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.